Iteos brings Glaxosmithkline a third checkpoint-targeting antibody in a $2B deal
Release Date:
Michel Detheux, president and CEO of Iteos Therapeutics Inc., discusses what his company brings GSK in a massive new deal. Hosted on Acast. See acast.com/privacy for more information.
Iteos brings Glaxosmithkline a third checkpoint-targeting antibody in a $2B deal